Comparison of transdermal alcohol concentration and self-reported alcohol consumption in people with alcohol dependence attending community alcohol treatment services

Brobbin, Eileen; Deluca, Paolo; Coulton, Simon; Parkin, Stephen; Drummond, Colin

doi:10.1016/j.drugalcdep.2024.111122

Cited by 2 publications

(3 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study will explore the feasibility of using a TAS and providing CM to people attending community alcohol treatment services. The design was consistent with a previous study conducted by the same research team [26]. This previous study found that most participants were willing to wear the TAS for longer and that staff believe that to be used in alcohol treatment it would be more clinically useful to have patients wear the TAS for longer than one week.…”

Section: Original Manuscriptsupporting

confidence: 72%

“…Previous work by this research team demonstrated the acceptability of the BACtrack® Skyn over one week with adults accessing treatment for alcohol dependence and a high correlation between the TAS and selfreport [26,27]. This present protocol follows a similar design but over a slightly longer time (two weeks rather than one) and with the addition of the CM component.…”

Section: Discussionmentioning

confidence: 97%

“…A previous study our research team conducted, using TAS with alcohol-dependent individuals accessing treatment, suggests that patients find TAS acceptable to wear in their day-to-day lives without interference with their usual activities [26,27]. While that study had no aim to reduce alcohol consumption, in the interview, many patients stated that simply seeing the TAS on their wrist made them think about their alcohol consumption.…”

Section: Original Manuscriptmentioning

confidence: 99%

See 2 more Smart Citations

Use of Transdermal Alcohol Sensors in Conjunction With Contingency Management to Reduce Alcohol Consumption in People With Alcohol Dependence Attending Alcohol Treatment Services: Protocol for a Pilot Feasibility Randomized Controlled Trial

Brobbin,

Deluca,

Parkin

et al. 2024

JMIR Res Protoc

Self Cite

View full text Add to dashboard Cite

Background: Wearable technology for objective, continuous and reliable alcohol monitoring has been developed. These are known as transdermal alcohol sensors (TAS). They can be worn on the wrist or ankle with the sensor pressed against the skin and can measure sweat vapours being emitted from the skin, to record transdermal alcohol concentration (TAC). Previous studies have investigated the accuracy and acceptability of the available TAS brands but there has been little research into their use in people with alcohol use disorders (AUD).Objective: This feasibility randomised controlled trial (RCT) aims to explore the feasibility, strengths, and limitations of using a TAS to monitor alcohol consumption in individuals in treatment for AUD with or without contingency management (CM) to promote abstinence or low-level alcohol consumption.Methods: Method: The target sample size is 30 (15 randomised to each group). Participants will be recruited through poster adverts in alcohol services. Both groups (control and CM) will wear the TAS (BACtrack Skyn) for two weeks in the context of their usual treatment, meeting with the researcher every other weekday. In the last meeting, the participants will complete a postwear survey on their experience of wearing the TAS. The CM group will also receive small financial incentives for low or no alcohol consumption, as measured by the TAS. On days where the TAC peak is below a set threshold (<115.660 ug/l), CM group participants will be rewarded with a £5 voucher. There are financial bonuses if this target is achieved on consecutive days. The researcher will monitor TAC for each day of the study at each research visit and allocate financial incentives to participants according to a set reinforcement schedule. Results: Results: The first participant was enrolled in June 2023 and the last in December 2023. Data analysis is underway and is estimated to be completed by June 2024. A total of 32 were enrolled in total. Conclusions: Conclusion: Most TAS brands have had limited application in clinical settings and most studies have included healthy adults rather than people with AUD. TAS has the potential to enhance treatment outcomes in clinical alcohol treatment. The accuracy, acceptability, and feasibility of TAS in people with AUD in clinical settings needs to be investigated. This is the first study to use TAS in specialised alcohol services with diagnosed AUD individuals currently receiving treatment from a south London alcohol service. Clinical Trial: Trial registration: ISRCTN, ISRCTN46845361. Registered 9 October 2023 -Retrospectively registered, https://www.isrctn.com/ISRCTN46845361. Method:The target sample size is 30 (15 randomised to each group). Participants will be recruited through poster adverts in alcohol services. Both groups (control and CM) will wear the TAS (BACtrack Skyn) for two weeks in the context of their usual Results: The first participant was enrolled in June 2023 and the last in December 2023. Data analysis is underway and is estimated to be completed by June 202...

show abstract

Section: Original Manuscriptsupporting

confidence: 72%

Section: Discussionmentioning

confidence: 97%

Section: Original Manuscriptmentioning

confidence: 99%

See 1 more Smart Citation

Use of Transdermal Alcohol Sensors in Conjunction With Contingency Management to Reduce Alcohol Consumption in People With Alcohol Dependence Attending Alcohol Treatment Services: Protocol for a Pilot Feasibility Randomized Controlled Trial

Brobbin,

Deluca,

Parkin

et al. 2024

JMIR Res Protoc

Self Cite

View full text Add to dashboard Cite

show abstract

Use of Transdermal Alcohol Sensors in Conjunction With Contingency Management to Reduce Alcohol Consumption in People With Alcohol Dependence Attending Alcohol Treatment Services: Protocol for a Pilot Feasibility Randomized Controlled Trial (Preprint)

Brobbin,

Deluca,

Parkin

et al. 2024

Preprint

View full text Add to dashboard Cite

BACKGROUND Wearable technology for objective, continuous, and reliable alcohol monitoring has been developed. These are known as transdermal alcohol sensors (TASs). They can be worn on the wrist or ankle with the sensor pressed against the skin and can measure sweat vapors being emitted from the skin, to record transdermal alcohol concentration (TAC). Previous studies have investigated the accuracy and acceptability of the available TAS brands, but there has been little research into their use in people with alcohol use disorders (AUD). OBJECTIVE This feasibility randomized controlled trial aims to explore the feasibility, strengths, and limitations of using a TAS to monitor alcohol consumption in individuals in treatment for AUD with or without contingency management (CM) to promote abstinence or low-level alcohol consumption. METHODS The target sample size is 30 (15 randomized to each group). Participants will be recruited through poster adverts at alcohol services. Both groups (control and CM) will wear the TAS (BACtrack Skyn) for 2 weeks in the context of their usual treatment, meeting with the researcher every other weekday. In the last meeting, the participants will complete a postwear survey on their experience of wearing the TAS. The CM group will also receive small financial incentives for low or no alcohol consumption, as measured by the TAS. On days where the TAC peak is below a set threshold (<115.660 g/L), CM group participants will be rewarded with a £5 (US $6.38) voucher. There are financial bonuses if this target is achieved on consecutive days. The researcher will monitor TAC for each day of the study at each research visit and allocate financial incentives to participants according to a set reinforcement schedule. RESULTS The first participant was enrolled in June 2023, and the last in December 2023. Data analysis is underway and is estimated to be completed by June 2024. A total of 32 participants were enrolled. CONCLUSIONS Most TAS brands have had limited application in clinical settings, and most studies have included healthy adults rather than people with AUD. TAS has the potential to enhance treatment outcomes in clinical alcohol treatment. The accuracy, acceptability, and feasibility of TAS for people with AUD in clinical settings need to be investigated. This is the first study to use TAS in specialized alcohol services with diagnosed AUD individuals currently receiving treatment from a south London alcohol service. CLINICALTRIAL ISRCTN Registry ISRCTN46845361; https://www.isrctn.com/ISRCTN46845361 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/57653

show abstract

Comparison of transdermal alcohol concentration and self-reported alcohol consumption in people with alcohol dependence attending community alcohol treatment services

Cited by 2 publications

References 48 publications

Use of Transdermal Alcohol Sensors in Conjunction With Contingency Management to Reduce Alcohol Consumption in People With Alcohol Dependence Attending Alcohol Treatment Services: Protocol for a Pilot Feasibility Randomized Controlled Trial

Use of Transdermal Alcohol Sensors in Conjunction With Contingency Management to Reduce Alcohol Consumption in People With Alcohol Dependence Attending Alcohol Treatment Services: Protocol for a Pilot Feasibility Randomized Controlled Trial

Use of Transdermal Alcohol Sensors in Conjunction With Contingency Management to Reduce Alcohol Consumption in People With Alcohol Dependence Attending Alcohol Treatment Services: Protocol for a Pilot Feasibility Randomized Controlled Trial (Preprint)

Contact Info

Product

Resources

About